9th Nov 2021 09:08
Oxford Nanopore Technologies PLC - Oxford, England-based genomics firm specialising in DNA sequencing - Awarded three-year contract worth USD68 million by G42 Laboratory LLC for a large-scale human genomics project in the United Arab Emirates. Oxford Nanopore will provide devices and consumables, including flow cells and kits, and other support services. It notes that an affiliate of G42 Laboratory is a shareholder. The company had mentioned the possibility of the contract in a trading update last month.
Oxford Nanopore kept revenue guidance for its core Life Science Research Tools arm at GBP105 million to GBP111 million in 2021 but set 2022 guidance at GBP135 million to GBP145 million. For 2023, it expects LSRT revenue of GBP170 million to GBP190 million, up from GBP165 million to GBP175 million at the time of its initial public offering in September. All figures are at constant currency.
Current stock price: 570.00 pence, up 4.5% on Tuesday
Year-to-date change: up 34% from 425p IPO price
By Tom Waite; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Nano